Zevra Therapeutics (ZVRA) Receivables - Other (2015 - 2024)

Zevra Therapeutics (ZVRA) has 10 years of Receivables - Other data on file, last reported at $333000.0 in Q4 2024.

• Quarterly Receivables - Other fell 73.53% year-over-year to $333000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $333000.0 (down 73.53% YoY) and the FY2024 annual result came in at $333000.0, down 73.53% from the prior year.
• Receivables - Other eased to $333000.0 in Q4 2024, from $1.3 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.3 million in Q4 2023 to a low of $107000.0 in Q4 2021.
• A 5-year average of $543625.0 and a median of $366500.0 in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other jumped 941.12% — and 2024, when it plunged 73.53%.
• Tracing ZVRA's Receivables - Other over 5 years: stood at $137000.0 in 2020, then slipped by 21.9% to $107000.0 in 2021, then jumped by 941.12% to $1.1 million in 2022, then increased by 12.93% to $1.3 million in 2023, then sank by 73.53% to $333000.0 in 2024.
• The last three Receivables - Other figures came in at $333000.0 (Q4 2024), $1.3 million (Q4 2023), and $700000.0 (Q1 2023), per Business Quant data.